Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Income from Continuing Operations (2019 - 2025)

Bioadaptives' Income from Continuing Operations history spans 7 years, with the latest figure at 379502.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 908.0% year-over-year to 379502.0; the TTM value through Sep 2025 reached 1196263.0, down 411.34%, while the annual FY2024 figure was 694068.0, 155.19% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 379502.0 at Bioadaptives, down from 157914.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 19095.0 in Q4 2023 and bottomed at 491903.0 in Q1 2021.
  • The 5-year median for Income from Continuing Operations is 138754.0 (2022), against an average of 189626.63.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 116.34% in 2023 before it crashed 2196.72% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 89602.0 in 2021, then plummeted by 30.41% to 116851.0 in 2022, then surged by 116.34% to 19095.0 in 2023, then plummeted by 2196.72% to 400369.0 in 2024, then increased by 5.21% to 379502.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Income from Continuing Operations are 379502.0 (Q3 2025), 157914.0 (Q2 2025), and 258478.0 (Q1 2025).